Table 1

Summary of gene hypermethylation in kidney cancer

VHLRASSF1Ap16p14APCMGMTGSTP1RARβ2E-cadaTimp-3
Clear cell16% 8/5046% 23/508% 4/5012% 6/5010% 5/506% 3/5010% 5/508% 4/5014% 7/5060% 30/50
Papillary0% 0/2070% 14/2020% 4/2020% 4/2020% 4/2010% 2/2020% 4/2020% 4/2015% 3/2045% 9/20
Chromophobe0% 0/617% 1/60% 0/633% 2/60% 0/60% 0/60% 0/617% 1/60% 0/6100% 6/6
Oncocytoma0% 0/714% 1/714% 1/714% 1/729% 2/714% 1/714% 1/70% 0/70% 0/729% 2/7
Collecting duct0% 0/560% 3/50% 0/520% 1/520% 1/520% 1/50% 0/520% 1/50% 0/540% 2/5
RCC unclassified0% 0/520% 1/50% 0/540% 2/520% 1/50% 0/520% 1/520% 1/520% 1/560% 3/5
TCC renal pelvis0% 0/633% 2/617% 1/617% 1/617% 1/60% 0/60% 0/617% 1/60% 0/683% 5/6
Wilms’ tumor0% 0/10% 0/10% 0/10% 0/10% 0/10% 0/1100% 1/10% 0/10% 0/1100% 1/1
Kidney cancer8% 8/10045% 45/10010% 10/10017% 17/10014% 14/1007% 7/10012% 12/10012% 12/10011% 11/10058% 58/100
  • a E-cad, E-cadherin; RCC, renal cell carcinoma; TCC, transitional cell carcinoma.